A multicenter, randomised, parallel group, double-blind, placebo-controlled flexible dose study with an open-label extension to assess the efficacy and safety of Viagra (sildenafil citrate) in the treatment of men with erectile dysfunction (ED) and concomitant lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in the United States
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2007
At a glance
- Drugs Sildenafil (Primary)
- Indications Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms
- Focus Therapeutic Use
- 05 Nov 2005 New trial record.